$2.57 Billion is the total value of Flagship Pioneering Inc.'s 22 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 8.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRNA | Moderna Inc | $1,979,145,990 | -14.5% | 12,886,743 | 0.0% | 76.91% | +4.1% | |
| Buy | Omega Therapeutics Inc | $176,230,242 | -40.0% | 29,225,579 | +12.8% | 6.85% | -26.9% | |
| MCRB | Seres Therapeutics Inc | $131,073,645 | +1.2% | 23,117,045 | 0.0% | 5.09% | +23.2% | |
| SANA | Sana Biotechnology Inc | $111,961,589 | -17.2% | 34,239,018 | 0.0% | 4.35% | +0.8% | |
| FHTX | Foghorn Therapeutics Inc | $78,579,544 | -2.8% | 12,674,120 | 0.0% | 3.05% | +18.3% | |
| DNLI | Denali Therapeutics Inc | $60,364,063 | -17.2% | 2,619,968 | 0.0% | 2.35% | +0.9% | |
| AXLA | Axcella Health Inc | $14,040,740 | +50.0% | 29,251,545 | 0.0% | 0.55% | +82.6% | |
| SGTX | Sigilon Therapeutics Inc | $9,645,480 | +165.7% | 10,370,369 | 0.0% | 0.38% | +223.3% | |
| EVLO | Evelo Biosciences Inc | $9,112,219 | -88.8% | 50,427,328 | 0.0% | 0.35% | -86.3% | |
| Syros Pharmaceuticals Inc | $2,653,574 | -25.6% | 993,848 | 0.0% | 0.10% | -9.6% | ||
| CDAK | Codiak Biosciences Inc | $617,841 | -55.3% | 3,540,636 | 0.0% | 0.02% | -45.5% | |
| RUBY | Exit | Rubius Therapeutics Inc | $0 | – | -38,506,526 | -100.0% | -0.21% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Flagship Ventures Fund V General Partner LLC #1
- Flagship Ventures Fund IV General Partner LLC #2
- Noubar Afeyan #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SERES THERAPEUTICS INC | 29 | Q3 2023 | 68.0% |
| DENALI THERAPEUTICS INC | 24 | Q3 2023 | 50.9% |
| SYROS PHARMACEUTICALS INC | 24 | Q2 2022 | 27.3% |
| MODERNA INC | 20 | Q3 2023 | 76.9% |
| EVELO BIOSCIENCES INC | 20 | Q1 2023 | 41.2% |
| RUBIUS THERAPEUTICS INC | 18 | Q4 2022 | 60.7% |
| Axcella Health Inc | 17 | Q2 2023 | 3.5% |
| KALEIDO BIOSCIENCES INC | 13 | Q1 2022 | 9.5% |
| Foghorn Therapeutics Inc | 12 | Q3 2023 | 6.5% |
| Sana Biotechnology Inc | 11 | Q3 2023 | 18.4% |
View Flagship Pioneering Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-15 |
| 4 | 2023-08-15 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-07-13 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-02-27 |
| 13F-HR | 2023-02-14 |
View Flagship Pioneering Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.